NCF1B

Across TCGA pan-cancer cohorts, NCF1B Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated NCF1B data layer compared with 22 for mass-spec protein.

The strongest signal is observed in brain lower grade glioma (LGG), where higher NCF1B Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated NCF1B expression acts as an unfavorable survival marker.

LGG, BLCA, and PRAD are the cancer types where NCF1B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LGG	OS	Median	All	0.173	0.810	<.001	12	view →
BLCA	DFS	Median	III,IV	0.139	0.572	.026	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

NCF1B–LGG (OS)

Open the LGG breakdown →